Dr. Bernhard Klemen

bit.bio is an award-winning human synthetic biology company - our mission: coding cells for novel cures. We have developed an end-to-end platform for the creation of any human cell type. With our cutting-edge and patent-protected opti-ox precision cell programming technology, we can deterministically program human iPSCs into a chosen cell identity with unprecedented biological consistency at an industrial scale, and approximately 10 times faster than conventional methods. Our platform has the potential to unlock a new generation of medicines. Our io Cells research products provide scientists access to highly characterised, consistent, scalable human cells that enable research and drug discovery teams to accelerate their experimental timelines and reduce experimental variability, providing an important alternative to traditional workflows. We are also leveraging our platform to build a pipeline of txCells for cell therapies. To achieve our goals, we have assembled a team of pioneers in stem cell biology, cell programming, mathematical modelling and cell therapy. We are empirical, highly ambitious and driven by a shared vision. Collaboration is at the heart of bit.bio. Join us on our journey. For more information on bit.bio’s trademarks, visit www.bit.bio/trademarks

Covirabio GmbH is a young Start-Up company with the vision to enable pathogen detection and immune monitoring at the Point-of-Care or Point-of-Need. Based on the Covirabio technology platform VERB (Virus Entry Receptor Binding), a portfolio of test systems for the detection of SARS-CoV-2 infections or the immune response to an infection and/or vaccination is currently being developed. For the use at the Point-of-Care or Point-of-Need, the assays are integrated into microfluidic systems. This technology platform is now also expanded to bacterial pathogens.

At aTENSION.life, we develop and market innovative and precise diagnostic solutions that enable early and accurate diagnosis as well as targeted - and even personalized - treatment for people with hypertension. Our proprietary ALDO+ technology platform is based on state-of-the-art mass spectrometry and analyzes the Renin-Angiotensin-Aldosterone System (RAAS) with unparalleled precision from a single blood sample. This allows physicians to accurately identify the causes of treatment-resistant hypertension, without the need for trial-and-error approaches. The first product from this platform, ALDO+PA, is a CE-IVD-certified blood test for the diagnosis of Primary Aldosteronism (PA), one of the most common yet often overlooked causes of treatment-resistant hypertension. ALDO+PA delivers reliable results without requiring patients to stop their current medication and is available in Austria through our partnership with labors.at. With our scalable Prep’n’Ship™ model, we make mass spectrometry-based precision diagnostics accessible to any laboratory - regardless of existing infrastructure. We collaborate with physicians, laboratories, and healthcare institutions to set new standards in hypertension diagnostics and sustainably improve cardiovascular care.

bit.bio is an award-winning human synthetic biology company - our mission: coding cells for novel cures. We have developed an end-to-end platform for the creation of any human cell type. With our cutting-edge and patent-protected opti-ox precision cell programming technology, we can deterministically program human iPSCs into a chosen cell identity with unprecedented biological consistency at an industrial scale, and approximately 10 times faster than conventional methods. Our platform has the potential to unlock a new generation of medicines. Our io Cells research products provide scientists access to highly characterised, consistent, scalable human cells that enable research and drug discovery teams to accelerate their experimental timelines and reduce experimental variability, providing an important alternative to traditional workflows. We are also leveraging our platform to build a pipeline of txCells for cell therapies. To achieve our goals, we have assembled a team of pioneers in stem cell biology, cell programming, mathematical modelling and cell therapy. We are empirical, highly ambitious and driven by a shared vision. Collaboration is at the heart of bit.bio. Join us on our journey. For more information on bit.bio’s trademarks, visit www.bit.bio/trademarks

Ageing is natural but not inevitable. Some cells never age. Imagine if we could decode their rejuvenation programme. Imagine if we could prevent the diseases caused by ageing cells. Imagine a future where health is our default state

Early stage venture capital firm investing in Pakistani startups.